High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

Hon Y. Chan, Frederick J Meyers, Jerry P. Lewis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

Original languageEnglish (US)
Pages (from-to)265-266
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume20
Issue number3
DOIs
StatePublished - Sep 1987

Fingerprint

Cytarabine
Etoposide
Acute Myeloid Leukemia
Bone Marrow
Bone
Necrosis
Therapeutics
Recurrence

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. / Chan, Hon Y.; Meyers, Frederick J; Lewis, Jerry P.

In: Cancer Chemotherapy and Pharmacology, Vol. 20, No. 3, 09.1987, p. 265-266.

Research output: Contribution to journalArticle

@article{e9d7236afc6b4ea39d3f925af98eb843,
title = "High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia",
abstract = "In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.",
author = "Chan, {Hon Y.} and Meyers, {Frederick J} and Lewis, {Jerry P.}",
year = "1987",
month = "9",
doi = "10.1007/BF00570500",
language = "English (US)",
volume = "20",
pages = "265--266",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

AU - Chan, Hon Y.

AU - Meyers, Frederick J

AU - Lewis, Jerry P.

PY - 1987/9

Y1 - 1987/9

N2 - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

AB - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

UR - http://www.scopus.com/inward/record.url?scp=0023627491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023627491&partnerID=8YFLogxK

U2 - 10.1007/BF00570500

DO - 10.1007/BF00570500

M3 - Article

C2 - 3677301

AN - SCOPUS:0023627491

VL - 20

SP - 265

EP - 266

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -